Production (Stage)
Atara Biotherapeutics, Inc.
ATRA
$7.80
$0.3054.07%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 399.46% | 42.06% | -15.01% | 40.01% | 47.47% |
| Total Depreciation and Amortization | 63.18% | -10.57% | -7.52% | -4.39% | 15.44% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 48.74% | -5.93% | -3.15% | -16.22% | -22.55% |
| Change in Net Operating Assets | -266.49% | -441.44% | 293.97% | 71.17% | -61.23% |
| Cash from Operations | -14.99% | -513.46% | 62.53% | 64.05% | 41.25% |
| Capital Expenditure | -- | -- | 100.00% | 77.17% | -188.64% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 396.22% | 120.80% | -330.66% | -51.33% | 48.62% |
| Cash from Investing | 409.45% | 120.26% | -331.59% | -51.10% | 48.00% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -6.38% | -19.29% | 15.45% | -2.64% | -5.58% |
| Issuance of Common Stock | -- | -- | 54,537.63% | -99.01% | 442.79% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | -7,955.98% | -101.23% | -- |
| Cash from Financing | 23.78% | -100.92% | 11,147.22% | -101.34% | 1,496.63% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 47.77% | -241.51% | 501.25% | -140.81% | 123.74% |